Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’ Tasigna Approved By FDA For CML Patients Resistant to Gleevec

This article was originally published in The Pink Sheet Daily

Executive Summary

The Bcr-Ab1 inhibitor will be available in the U.S. “within days,” the company says.

You may also be interested in...



Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise

Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.

Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise

Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.

Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML

Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel